Primary chest wall lymphoma: A rare entity

Shah, Binay Kumar
July 2015
Journal of Cancer Research & Therapeutics;Jul-Sep2015, Vol. 11 Issue 3, Special section p661
Academic Journal
case study
Primary chest wall lymphoma is a rare but curable condition. This paper reports a case of a 52-year-old female patient who presented with a primary chest wall diffuse large B-cell lymphoma.


Related Articles

  • Treatment Strategies for Diffuse Large B Cell Lymphoma. Thieblemont, Catherine; Gisselbrecht, Christian // Current Medical Literature: Leukemia & Lymphoma;2010, Vol. 18 Issue 3, p57 

    The article discusses treatments for diffuse large B cell lymphoma (DLBCL). Considered as the most usual form of adult non-Hodgkin lymphoma (NHL), first line treatment for the disease is the combination therapy rituximab with cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP)....

  • Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL. Song, Moo-Kon; Chung, Joo-Seop; Kim, Seong-Jang; Kim, Sang-Soo; Shin, Ho-Jin // Annals of Hematology;Jun2015, Vol. 94 Issue 6, p995 

    Therapy-induced autoimmunity may mediate the destruction of cancer cells. Previous studies have demonstrated that presence of autoimmune thyroid disorder is associated with favorable outcome in patients with solid cancer. Patients with diffuse large B cell lymphoma (DLBCL) who achieved complete...

  • Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Lerch, K.; Meyer, A.; Stroux, A.; Hirt, C.; Keller, U.; Viardot, A.; Marks, R.; Schreiber, S.; Pezzutto, A.; Scholz, C. // Annals of Hematology;Jun2015, Vol. 94 Issue 6, p981 

    Transformation of follicular lymphoma (FL) into aggressive disease and relapse of de novo diffuse large B cell lymphoma (DLBCL) are considered highly unfavourable events. However, most published data were acquired when rituximab was not routinely used. We retrospectively analysed 50 patients...

  • Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China. De Zhou; Li Li; Changqian Bao; Jingjing Zhu; Lixia Zhu; Xiudi Yang; Yanlong Zheng; Meng Zhou; Xuxia Luo; Wanzhuo Xie; Xiujin Ye // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 12, p22497 

    Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin's lymphoma (NHL) in adults, and approximately 50% of cases of DLBCL occur in patients above the age of 60. Although RCHOP regimen was established as the standard therapy for DLBCL patients, there are still a large...

  • Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy. Guo, Wei; Zhang, Wenxian; Liu, Chunshui; Song, Yuanyuan; Bai, Ou // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Objectives: This study aimed to determine the HBV infection status of 135 patients with DLBCL (diffuse large B cell lymphoma), to analyze the overall survival (OS) and progression-free survival (PFS) of the different HBV infection status groups, and to discuss the relationship between HBV...

  • Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature. Kiesewetter, Barbara; Ferreri, AndrĂ©s J.M.; Raderer, Markus // Oncologist;2015, Vol. 20 Issue 8, p915 

    Background. Biological treatments, chemoimmunotherapy, and radiotherapy are associated with excellent disease control in both gastric and extragastric mucosa-associated lymphoid tissue (MALT) lymphomas. Systemic treatment approaches with both oral and i.v. agents are being increasingly studied,...

  • Primary Mediastinal Large B-Cell Lymphoma during Pregnancy. Perez, Cesar A.; Amin, Janki; Aguina, Luz M.; Cioffi-Lavina, Maureen; Santos, Edgardo S. // Case Reports in Hematology;2012, p1 

    Non-Hodgkin's Lymphoma (NHL) rarely presents during pregnancy and primary mediastinal large B-cell lymphoma (PMLBCL) accounts for approximately 2.5% of patients with NHL. The case of a 22-year-old woman who was diagnosed with Stage IIA PMLBCL during week 13 of her intrauterine pregnancy is...

  • Antineoplastics.  // Reactions Weekly;1/30/2016, Vol. 1586 Issue 1, p44 

    An abstract of the article "Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma" by Y. Cui and others is presented.

  • FCGR3A 158V/F Polymorphism and Response to Frontline R-CHOP Therapy in Diffuse Large B-Cell Lymphoma. Liu, Fen; Ding, Huirong; Jin, Xuan; Ding, Ning; Deng, Lijuan; He, Yan; Zhu, Jun; Song, Yuqin // DNA & Cell Biology;Sep2014, Vol. 33 Issue 9, p616 

    The influence of Fc gamma receptor IIIA ( FCGR3A) 158V/F polymorphisms on the response to rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is uncertain. Thus, a retrospective study and a meta-analysis were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics